Sophia Abene

Addressing this threat requires the development of effective vaccines and therapeutics specifically targeting evolving H5N1 viruses.

Study highlights that many long-term symptoms may result from ongoing inflammation rather than persistent viral presence.

Pfizer's Phase 3 MONeT trial shows that Abrysvo is safe and effective in producing strong immune responses against RSV in immunocompromised adults.

Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B.

Part 1, Deborah Birx, MD explains photohydrolysis technology provides continuous, automated disinfection of air and surfaces effective in controlling MRSA and improving infection control practices in healthcare settings.

The expanded recall, which now includes approximately 7 million pounds of products, is due to an ongoing investigation linked to 43 reported illnesses, including 3 deaths.

By implementing targeted monitoring and a phased compliance approach, the USDA aims to enhance food safety and public health while maintaining cost-effectiveness and ensuring safer poultry products.

The study examines how pathogenicity-related gene clusters integrate into Salmonella's genome to affect disease ability.

This updated guidance incorporates new treatment strategies and recommendations based on the latest data on antimicrobial resistance.

A single-dose dengue vaccine that is effective across various age groups and independent of prior dengue exposure is essential.

There is a high potential for ActivePure Medical’s technology to enhance patient safety and reduce healthcare costs by minimizing harmful pathogens in complex healthcare environments.

Results demonstrate high safety and reduced need for oxygen supplementation in patients with COVID-19 viral pneumonia.

Analyzing data from over 4.6 million sinusitis cases, the study emphasizes the need for focused efforts to improve adherence to treatment guidelines and ensure antibiotics are used correctly.

Given that over 50% of women experience at least one urinary tract infection annually and antimicrobial resistance is on the rise, it's essential to evaluate the evidence for potential non-drug interventions.

The prevalence of methicillin-resistant Staphylococcus aureus has surged from 2.58% to 14.79%, highlighting a need for updated treatment strategies.

Providing nirsevimab (Beyfortus) to all newborns and high-risk infants during the 2024-2025 RSV season represents an advancement in protecting infant health.

Increased funding can lead to the development of resources like rapid diagnostic test kits and improve the overall availability of treatment for those in need.

Omadacycline (Nuzyra) maintained its potency over time and did not show a decrease in effectiveness.

HepB-BD is unavailable in 17 countries, and the number of young children receiving the HepB3 shot has dropped by 10 percentage points or more.

New study reveals a marked reduction in HCV infection rates, falling from 23.4% in 2017 to 6% in 2023.

Malaria control efforts can be impacted by indoor nuisance pest management as ineffective control of pests may erode community trust in vector control products.

This week, NYC has revealed high rates of Hepatitis C virus reinfection, SHEA tackles antimicrobial resistance amidst challenges during the COVID-19 pandemic, and more this week from Contagion.

Multimonth dispensing recipients show a notable decrease in discontinuation rates, highlighting its potential to improve long-term treatment adherence and retention in HIV care programs.

New insights might lead to updated treatments focusing on different viral entry routes, influencing COVID-19 and related conditions.

Three studies provide insights into the ongoing COVID-19 pandemic, the prevalence of post-COVID conditions among primary care patients, the effectiveness of nirmatrelvir/ritonavir treatment, and declines in primary care visits.

SHEA supports funding to address antimicrobial resistance in light of heightened challenges during the COVID-19 pandemic.

While the SCORPIO-HR phase 3 trial did not meet its primary endpoint of sustained symptom resolution, ensitrelvir showed promising results in reducing symptom duration and preventing viral rebound.

Despite advances in antiviral treatments, the study reveals that traditional prevention strategies have not curbed reinfection rates among men who have sex with men linked to specific high-risk behaviors.

Paratek Pharmaceuticals has announced results from a Phase 3 study of omadacycline (Nuzyra), demonstrating its non-inferiority to moxifloxacin in treating moderate to severe community-acquired bacterial pneumonia.

Participants using nasal sprays experienced significantly shorter illness durations and reduced antibiotic usage compared to those receiving usual care.